Thromboembolism in Older Adults
Authors:
Open Access
- 27 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7, 470016
Abstract
Arterial and venous thromboembolism are both more common in older adults. The use of anticoagulants, the mainstay to prevent thromboembolism, requires consideration of the balance between risk and benefit. Such consideration is even more important in the very elderly in whom the risk of anticoagulant-related bleeding and thrombosis are higher. This review will focus on the challenges of implementing and managing anticoagulant therapy in older patients in an era when the options for anticoagulants include not only vitamin K antagonists (VKAs), but also direct-acting oral anticoagulants (DOACs).Keywords
This publication has 88 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial FibrillationCirculation, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Outcomes and predictors of very stable INR control during chronic anticoagulation therapyBlood, 2009
- Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE studyJournal of Thrombosis and Thrombolysis, 2009
- The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillationAge and Ageing, 2008
- Hemostasis and ageingImmunity & Ageing, 2008
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Atrial Fibrillation Is Associated with Severe Acute Ischemic StrokeNeuroepidemiology, 2003